Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L H Lindner

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
International Journal of Hematology|October 7, 2008
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicityL H Lindner, H Ostermann, W Hiddemann, et al.
Leukemia|March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanismsA M Martelli, V Papa, P L Tazzari, et al.
Gynecologic Oncology|May 22, 2016
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapyI Ray-Coquard, E Rizzo, J Y Blay, et al.
ESMO Open|April 10, 2026
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trialG-E Schuebbe, Y Xu, L H Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'P Schöffski, A Wozniak, B Kasper, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Journal of Hematology|October 7, 2008
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicityL H Lindner, H Ostermann, W Hiddemann, et al.
Leukemia|March 5, 2010
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanismsA M Martelli, V Papa, P L Tazzari, et al.
Gynecologic Oncology|May 22, 2016
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapyI Ray-Coquard, E Rizzo, J Y Blay, et al.
ESMO Open|April 10, 2026
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trialG-E Schuebbe, Y Xu, L H Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2018
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'P Schöffski, A Wozniak, S Stacchiotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'P Schöffski, A Wozniak, B Kasper, et al.
Pageof 2